PAM2L Biotechnologies key facts
as of Oct 2026- Developer of biomaterial innovation and application intended for the synthetic biology sector.
- PAM2L Biotechnologies is valued at approximately $88.8M as of Oct 2026 (last reported valuation).
- It has raised $19.1M; the latest was Early Stage VC in Nov 2025.
- Notable investors include Co-Stone Capital, 5Y Capital, Yunqi Partners, Shenzhen Angel Investment Guiding Fund, Guangzhou Guangyao Capital — 11 tracked in total.
- Status: Privately Held (backing).
PAM2L Biotechnologies's last reported valuation, Jan 2023. Nothing priced has surfaced since.
- ·The complete investor list: 11 names
- ·Watch PAM2L Biotechnologies: the Monday email on marks, rounds and moves
PAM2L Biotechnologies funding rounds
No funding rounds for PAM2L Biotechnologies are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs PAM2L Biotechnologies
11+PAM2L Biotechnologies valuation
PAM2L Biotechnologies's last reported valuation was $88.8 million in Jan 2023. No priced round, secondary trade or fund mark has surfaced since.
PAM2L Biotechnologies investors
11 investors are on record for PAM2L Biotechnologies, including Co-Stone Capital, 5Y Capital, Yunqi Partners and Shenzhen Angel Investment Guiding Fund.
About PAM2L Biotechnologies
Developer of biomaterial innovation and application intended for the synthetic biology sector. The company mainly focuses on the development of protein and polysaccharide raw materials, thereby enabling customers to access safe, efficient, and sustainable biomaterial solutions.
- Sector
- Materials and Resources
- HQ
- Shenzhen, China
- Founded
- 2021
- Website
- pam2l.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.